Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CORRELATIONS OF LOW MOLECULAR WEIGHT PHENOTYPE OF APOPROTEIN(A) AND SERUM LEVEL OF LIPOPROTEIN(A) WITH MULTIFOCAL ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE

https://doi.org/10.20996/1819-6446-2010-6-4-474-480

Full Text:

Abstract

Background. Atherosclerosis is a systemic disease. That is why the damage is not restricted by one vascular area in 18-50% of patients. High serum level of lipoprotein(a) [Lp(a)] is an independent risk factor for coronary, carotid and peripheral atherosclerosis. However the correlation of apoprotein(a) [apo(a)] polymorphism with the multifocal atherosclerosis in coronary heart disease (CHD) is not sufficiently studied.

Aim. To study the correlation of apo(a) phenotype with the multifocal atherosclerosis in CHD patients.

Material and Methods. 220 patients aged 32- 76 y.o. with the proven coronary and carotid atherosclerosis were split into two groups depending on the presence (n=22) or absence (n=198) of peripheral atherosclerosis. Evaluation of lipid profile, Lp(a) and determination of apo(a) isoforms by SDS electrophoresis in polyacrylamide gel and immunoblotting was performed in all patients.

Results. Both groups of patients were comparable by age, sex, classical cardiovascular risk factors, including frequency of hyperlipidemia and diabetes mellitus, lipid profile. The Lp(a) serum level ≥30 mg/dL and low molecular weight (LMW) apo(a) phenotype were found more often in patients with multifocal than coronary and carotid atherosclerosis: 55 and 45% (р=0.372); 73 and 44% (p<0.05), respectively. According to multiple regression analysis (including sex, age, smoking status, and Lp(a) serum level) only smoking status (β=0.203, p=0.0003) and a size of apo(a) isoforms (β=0.191, p=0.0133) correlated with the peripheral atherosclerosis in patients with CHD. LMW apo(a) phenotype was the most significant predictor of peripheral atherosclerosis (β=0.281, p=0.0089) regardless of the Lp(a) serum level in patients under 55 y.o. High Lp(a) serum level combined with LMW apo(a) phenotype associated with more significant coronary, carotid and peripheral atherosclerosis.

Conclusion. LMW apo(a) phenotype relates to the presence of multifocal atherosclerosis in CHD patients regardless of the Lp(a) serum level. Apo(a) phenotype can be a marker of generalized atherosclerosis especially among young adults. Next studies of correlations Lp(a) and apo(a) phenotype with lower limb arteries lesions are needed in various patients.

About the Authors

O. I. Afanasieva
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


M. V. Ezhov
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


M. I. Afanasieva
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


M. S. Safarova
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


J. V. Berestetskaya
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


S. N. Pokrovsky
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


References

1. Чернявский А.М., Караськов А.М., Мироненко С.П., Ковляков В.А. Хирургическое лечение мультифокального атеросклероза. Бюллетень СО РАМН 2006; 2 (120): 126-131.

2. Jurgens G., Chen Q., EsterbauerH. et al. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb 1993;13(11):1689–1699.

3. Rath M., Niendorf A., Reblin T. et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9(5):579–592.

4. Kosсhinsky M., Marcovina S. Lipoprotein(a). in Ballantyne C.M. et al, editor. Clinical Lipidology: a companion to Braunwald’s heart disease. Saunders, and imprint of Elsevier Inc; 2009. P.130-143.

5. Sandholzer C., Hallman D.M., Saha N. et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86(6):607-614.

6. Geethanjali F.S., Luthra K., Lingenhel A. et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease.Atherosclerosis 2003;169(1):121- 130.

7. Ежов М.В., Афанасьева О.И., Беневоленская Г.Ф. и др. Липопротеид(а) как биохимический маркер коронарного атеросклероза. Терапевтический архив 1997; 9:31-34.

8. Ежов М.В., Афанасьева О.И., Беневоленская Г.Ф. и др. Связь липопротеида(а) и фенотипа апобелка (а) с атеросклерозом у мужчин с ишемической болезнью сердца. Терапевтический архив 2000; 1:28-32.

9. Pokrovsky S.N., Ezhov M.V., Il'ina L.N. et.al. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;126(4):1071-1075.

10. Bennet A., Di Angelantonio E., Erqou S. et al. Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease Large-Scale Prospective Data. Arch Intern Med 2008;168(6):598-608

11. Cheng S.W., Ting A.C., Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997;14(1):17-23.

12. Бритарева В.В., Афанасьева О.И., Добровольский А.Б. и др. Липопротеид(а) и изоформы апо(а) у больных с перемежающейся хромотой. Терапевтический архив 2002; 74 (12): 49-52.

13. Dieplinger B., Lingenhel A., Baumgartner N. et al. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem 2007;53(7):1298-1305.

14. Dahlen G.H. Incidence of Lp(a) lipoprotein among populations. In: Scanu A.M. (Ed.), Lipoprotein(a): 25 Years in Progress. Academic Press. Inc. 1990. P. 151-173.

15. Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида (а). Бюллетень экспериментальной биологии и медицины 1995; 10:398-401.

16. Kraft H.G., Dieplinger H., Hoye E., Utermann G. Lp(a) phenotyping by immunoblotting with polyclonal and monoclonal antibodies. Arteriosclerosis 1988;8(3):212-216.

17. Utermann G., Menzel H.J., Kraft H.G. et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80(2):458-465.

18. KraftH.G., LingenhelA., Bader G. et.al. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996;125(1):53- 61.

19. Pantoni L., Sarti C., Pracucci G. et al. Lipoprotein(a) serum levels and vascular diseases in an older Caucasian population cohort. Italian Longitudinal Study on Aging (ILSA). J Am Geriatr Soc 2001;49(2):117- 125.

20. Yamaguchi Y., Haginaka J., Morimoto S. et al. Facilitated nitration and oxidation of LDL in cigarette smokers. EurJ Clin Invest 2005;35(3):186- 193.

21. Bergmark C., Dewan A., Orsoni A. et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49(10): 2230–2239.

22. Tsimikas S., Clopton P., Brilakis E. et al. Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Results From the Dallas Heart Study. Circulation 2009;119(13):1711-1719.


For citation:


Afanasieva O.I., Ezhov M.V., Afanasieva M.I., Safarova M.S., Berestetskaya J.V., Pokrovsky S.N. CORRELATIONS OF LOW MOLECULAR WEIGHT PHENOTYPE OF APOPROTEIN(A) AND SERUM LEVEL OF LIPOPROTEIN(A) WITH MULTIFOCAL ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2010;6(4):474-480. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-474-480

Views: 622


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)